While we continue to pursue and invest in additional therapies in early and late stages of clinical development (see Worldwide Research & Development (WRD) and Biopharmaceuticals pages), the following are Pfizer's priority R&D therapeutic areas:
NOTE: For opportunities that fall into the pre-clinical proof of concept space, generally before phase 2b of development, visit the WRD links below. For post-clinical proof of concept, generally post phase 2a of development, visit the biopharmaceutical business units.
- Cardiovascular and Metabolic Disease
- Pain and Sensory